Company / Accounts Receivable
Apellis Pharmaceuticals, Inc. Accounts Receivable History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$366.2M
FY2025
5-year range
$7.7M / $366.2M
FY2021-FY2025
Trend
+38.2%
vs FY2024
Sector context
#26 of 113
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s accounts receivable of $366M is higher than 77% of companies in the Health Care sector (FY2025). Accounts Receivable has increased for 3 consecutive years, from $8M in FY2022 to $366M in FY2025.
Based on SEC 10-K filings.
$366M in FY2025 with a 3-year CAGR of +261.9%. Top quartile in the Health Care sector.
Improved from $206M to $366M over the past 2 years.
Health Care sector context is included.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +261.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-67.8% below sector average
Key checks
Key Insights
- Apellis Pharmaceuticals, Inc.'s accounts receivable has grown for 3 consecutive years.
- 3-year CAGR of +261.9%, indicating consistent growth.
- In FY2025, accounts receivable increased 38.2% year-over-year.
- Ranks #26 out of 113 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $366.2M | +38.2% |
| FY2024 | $264.9M | +28.3% |
| FY2023 | $206.4M | +2571.7% |
| FY2022 | $7.7M | -23.5% |
| FY2021 | $10.1M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026